Image Image Image Image Image Image Image Image Image Image
Access
Up

Up

What sets us apart? 

360º MEDICINE

Alongside medical rigour we offer additional benefits, providing all our patients with comprehensive care through a programme of exclusive services at no extra cost.

  • Psychological support.
  • Nutritional counselling.
  • Advice on assistive technologies.
  • Patient accompaniment service.
Among other services. + See more

News + See all news items

amd3
21/11/2019.Dr Jordi Monés explains the huge impact of atrophic AMD at the Iveric Bio Zymura Investors R&D Science Day
Dr Jordi Monés MD, PhD, the Director of the Institut de la Màcula, took part at the Iveric B...

News

supermarket-949913_1920
18/11/2019.A model app for accessibility: the supermarket on your mobile phone
Digitisation has led every company to offer their services through this route. Although this c...

News

father-and-son-1436335-1599x1141
14/11/2019.World Diabetes Day: the disease, its effect on vision and the family’s role
Diabetes is a chronic disease whose complications can lead to various eye pathologies, such...

News

PHOTO-2019-11-11-17-55-48 (1)
08/11/2019.Dr Jordi Monés addresses at the 15th ISOPT the latest developments in the Lucerne and Rhine trials
The Director del Institut de la Màcula, Dr Jordi Monés MD, PhD, was a protagonist at the pre...

News

Research + See all research

IM_Captura-4-1024x681
13/11/2019.Research project MICROBEYEOME

 

IF YOU WANT TO PARTICIPATE IN A CLINICAL TRIAL, SEND US YOUR DATA HERE AND WE WILL EVALUATE IF YOU ARE ELEGIBLE

Description

Age-related macular degeneration (AMD) is the leading cause of vision loss in people of over 50 in developed countries. Although the risk factors for the disease have been widely catalogued, its causes continue to be little known.

In recent years, there has been an exponential increase in research on the association between the intestinal microbiota and the diseases that affect humans.

Principal inclusion criteria

Patients of over 50, with age-related macular degeneration and healthy patients.

The patients must not have taken antibiotics in the past three months.

Patients with other neurodegenerative diseases such as Alzheimer's disease or Parkinson's disease, or those in treatment for any type of cancer, will be excluded.

Aim

The MICROBEYEOME study attempts to characterise the intestinal and oral microbiome of the patients diagnosed with AMD through RNA 16S sequencing and compare it with the microbiome of healthy patients, thereby identifying whether a single microbial composition may be associated with a specific phenotype. Given that the intestinal microbiome is potentially modifiable, this study could open new avenues of research for the prevention and/or possible treatment of AMD.

Duration

This initial phase of the trial consists of a single visit.

Consortium partners

Institut de la Màcula
Barcelona Macula Foundation
 Centre for Genomic Regulation

 

...

Research Recruiting

DMAE exsudativa (1)
09/04/2019.LUCERNE clinical trial: efficacy and safety of FARICIMAB regarding aflibercept in the treatment of exudative age-related macular degeneration

IF YOU WANT TO PARTICIPATE IN A CLINICAL TRIAL, SEND US YOUR DATA HERE AND I WILL EVALUATE IF YOU ARE ELIGIBLE

Description

This is a multicentre, randomized and double-masking Clinical Trial Phase III of two parallel groups that evaluates the efficacy and safety of faricimab administered by intravitreal injeccions in patients with exudative age-related macular degenereation (AMD) compared to treatment with aflibercept (EYLEA®).

 Main inclusion criteria

Patients over 50 years of exudative age-related macular degeneration who have not received study’s treatment for this eye disease

Visual acuity should be between 20/32 and 20/320.

 Goal

The main objective is to demonstrate the efficacy of faricimab compared with aflibercept regarded the visual acuity result one year later

About the medicine

Faricimab is the first bispecific monoclonal antibody designed for intravitreal use that combines the antiangiogenic action of the medicine currently used for the AMD’s treatment with the anti-inflammatory action, neutralizing VEGF and angiopoietin-2 at the same time. The results in previous studies support the beginning of a Phase III trial to evaluate the efficacy and safety of faricimab in the treatment of neovascular AMD patients, in order to increase the intervals between treatments.

 Duration

This essay lasts for two years.

IF YOU WANT TO PARTICIPATE IN A CLINICAL TRIAL, SEND US YOUR DATA HERE AND I WILL EVALUATE IF YOU ARE ELIGIBLE

...

Research

AGF-DME
03/03/2019.RHINE – Phase III study in the treatment of diabetic macular oedema

IF YOU WANT TO PARTICIPATE IN A CLINICAL TRIAL, SEND US YOUR DATA HERE AND I WILL EVALUATE IF YOU ARE ELIGIBLE

Description:

This is a phase III, multi-centre, randomised, double-masked, three-group trial that assesses the efficacy and safety of RG7716 administered through intravitreal injections in adult patients with visual disturbance due to diabetic macular oedema (DMO) in comparison with the administration of aflibercept (EYLEA®).

Principal inclusion criteria:

Patients of over 18 years of age with type 1 or 2 diabetes mellitus and visual disturbance due to diabetic macular oedema in the study eye without previous treatment with any anti-VEGF drug or who have not received it in the past three months.

Visual acuity should be between 20/32 and 20/320.

Aim:

The main aim is to demonstrate that RG7716 is not inferior to aflibercept with respect to visual outcome after the first year of treatment.

About the drug:

RG7716 is an antibody that inhibits for the first time and simultaneously two factors, VEGF-A and Angiopoietin 2, producing a priori improved control of the mechanisms that induce diabetic macular oedema.

Duration:

This trial has a duration of two years.

*Institut Registration Code: E08607500. Clinical trial authorised by the Spanish Agency of Medicines and Medical Devices (AEMPS) and the CEIm of the Quironsalud Hospital Group in Barcelona.

IF YOU WANT TO PARTICIPATE IN A CLINICAL TRIAL, SEND US YOUR DATA HERE AND I WILL EVALUATE IF YOU ARE ELIGIBLE

...

Research

EMD_OCT negre
03/10/2018.Clinical trial THR-317-002: Efficacy and safety of THR-317 with ranibizumab in the treatment of diabetic macular oedema

Description

A randomized, single-masked, multicenter, phase II clinical trial to evaluate the safety and efficacy of a new treatment, THR-317 (8 mg), in combination with ranibizumab 0.5 mg, vs sham THR-317 injection and ranibizumab 0.5 mg, in patients with diabetic macular edema (DME).

Inclusion criteria

Patients with central DME without previous anti-VEGF treatment or with poor response to previous treatment with ranibizumab 0.5 mg. according to specific criteria.

Aim

To determine the safety and efficacy of THR-317 (8 mg) in combination with ranibizumab 0.5 mg as evaluated by best-corrected visual acuity change at month 3 as compared to baseline.

About the drug

THR-317 is an immunoglobulin G recombinant humanized monoclonal antibody directed against the Placental Growth Factor (PlGF) receptors types 1 and 2.

Who can participate

Patients with types 1 or 2 diabetes mellitus and DME with a visual acuity between 20/40 and 20/320, and without previous anti-VEGF treatment or with a poor response (as defined in the Protocol) to ranibizumab 0.5 mg. after a minimum of 3 intravitreal injections, the last one of which should have taken place 1 year previous to the screening visit as maximum. Further criteria apply.

Study duration

Approximately 5 months (140 days)

If you are interested in taking part in a clinical trial, please send us your personal details here and we will assess whether you are eligible.

 

PilarRuiz_red1

 

...

Research

International patients

Do you live outside Barcelona but would like to be treated at the Institut de la Màcula? Enter here and find all the information you need.

Help us prevent degenerative eye diseases. The BMF researches effective treatments to reverse ever more forms of blindness. Collaborate with the Barcelona Macula Foundation: Research for Vision

BMF-transp
Last modified: 22 November, 2019 - 11:55